ATC Group: G03AC Progestogens

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G03AC in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G03 Sex hormones and modulators of the genital system
3 G03A Hormonal contraceptives for systemic use
4 G03AC Progestogens

Group G03AC contents

Code Title
G03AC01 Norethisterone
G03AC02 Lynestrenol
G03AC03 Levonorgestrel
G03AC04 Quingestanol
G03AC05 Megestrol
G03AC06 Medroxyprogesterone
G03AC07 Norgestrienone
G03AC08 Etonogestrel
G03AC09 Desogestrel
G03AC10

Active ingredients in G03AC

Active Ingredient

Desogestrel is a progestogen. Like other progestogen-only pills, desogestrel is best suited for use during breast feeding and for women who may not or do not want to use oestrogens. In contrast to traditional progestogen-only pills, the contraceptive effect of desogestrel is achieved primarily by inhibition of ovulation. Other effects include increased viscosity of the cervical mucus.

Etonogestrel is the biologically active metabolite of desogestrel, a progestagen widely used in OCs. It is structurally derived from 19-nortestosterone and binds with high affinity to progesterone receptors in the target organs. The contraceptive effect of etonogestrel is primarily achieved by inhibition of ovulation.

The precise mode of action of levonorgestrel as an emergency contraceptive is not known. At the recommended regimen, levonorgestrel is thought to work mainly by preventing ovulation and fertilisation if intercourse has taken place in the preovulatory phase, when the likelihood of fertilisation is the highest.

Lynestrenol is an oral preparation of the synthetic progestagen, which shares various activities with the natural hormone progesterone. Lynestrenol has a strong progestational influence on the endometrium. In addition it suppresses the ovulation and menstruation for as long as the preparation is taken daily without interruption.

Medroxyprogesterone acetate exerts anti-oestrogenic, anti-androgenic and antigonadotrophic effects.

Megestrol possesses pharmacological properties similar to those of natural progesterone. Megestrol acetate is a potent progestogen that exerts significant anti-oestrogenic effects. It has no androgenic or oestrogenic properties.

Norethisterone has progestational actions similar to those of progesterone, but is a more potent inhibitor of ovulation and has weak oestrogenic and androgenic properties. It is used to treat a number of disorders of the menstrual cycle.

Related product monographs

Document Type Information Source  
 AZALIA Film-coated tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 CERAZETTE Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 DEPO-PROVERA Suspension for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 IMPLANON NXT Implant for subdermal use MPI, EU: SmPC Health Products Regulatory Authority (IE)
 JADELLE Implant MPI, EU: SmPC Medicines and Medical Devices Safety Authority (NZ)
 JENCYCLA Tablet MPI, US: SPL/Old FDA, National Drug Code (US)
 MICROLUT Sugar-coated tablet MPI, EU: SmPC Medicines and Medical Devices Safety Authority (NZ)
 MICROVAL Coated tablet MPI, EU: SmPC Web Search
 NEXPLANON Implant MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 NORIDAY Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 NORISTERAT Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 NORLEVO Tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 PROVERA Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 SAYANA Suspension for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 UTOVLAN Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)